Edgewise Therapeutics Inc (EWTX) — Institutional Investor Activity (Q2 2026)

EWTX ranks #2685 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

EWTX is a top-conviction position for Novo Holdings A/S — at 12.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in EWTX belongs to Orbimed Advisors LLC, but the position matters far more to Novo Holdings A/S, who has 12.6% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Paradigm Biocapital Advisors LP has added to its EWTX position for two straight quarters, increasing it by $252.7M to reach $415.1M today.

UBS Group AG has trimmed its EWTX position for two straight quarters, cutting it by $45.4M while still holding $7.1M.

EWTX is down 0.6% today, but institutions show net buying of $295.0M this quarter — a divergence between today's price move and the underlying institutional flow.

EWTX reported a net loss of $167.8M in its latest fiscal year.

• Not yet profitable — net loss of $167.8M in the latest fiscal year
• Net income declined year over year, from -$133.8M to -$167.8M
• Operating cash flow was negative, using $143.8M in cash
• Current ratio of 19.85x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.06x equity — within a conventional range